Drugs / GSK2878175
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02014571 | Dec 2013 → Jul 2014 | chronic hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01879462 | Jun 2013 → Jan 2014 | chronic hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2878175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02014571 ↗ |
| Action | Inhibit | “NS5B non-nucleoside inhibitor (NNI)” NCT01879462 ↗ |
| Modality | Small molecule | “GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic HCV infection.” NCT01879462 ↗ |
| Route | Oral | “Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.” NCT01879462 ↗ |